返回 
加入收藏
胰高血糖素样肽1受体激动剂类药物用药指导（2023版）
x
请在关注微信后，向客服人员索取文件
| 篇名： | 胰高血糖素样肽1受体激动剂类药物用药指导（2023版） |
| TITLE： | Medication guidelines for glucagon-like peptide-1 receptor agonist （2023 edition） |
| 摘要： | 我国糖尿病患病率呈逐年上升趋势，已成为全社会密切关注的健康问题。胰高血糖素样肽1（GLP-1）受体激动剂（GLP-1RA）作为一类新型降糖药物，因降糖疗效显著、低血糖发生风险低等优势，现被广泛应用于2型糖尿病（T2DM）的治疗。随着其改善心血管、保护肾脏以及减轻体质量等作用的证据等级的不断完善，该类药物在T2DM治疗指南中的地位逐渐提高。目前我国已批准9种GLP-1RA类药物用于临床治疗T2DM，这类药物虽然均基于激活体内GLP-1受体而发挥降糖作用，但由于药物自身结构和天然GLP-1氨基酸同源性的差异，导致不同药物间的药动学参数和临床疗效等差异较大。为使临床医生和药师全面了解该类药物的特点和临床证据，更好地发挥治疗作用，辽宁省药学会组织临床医学和药学专家，整理汇总了9种GLP-1RA类药物的药学特性、临床应用、不良反应、相互作用、特殊人群用药以及用药管理，制定了GLP-1RA类药物用药指导，为临床用药提供参考，促进该类药物的合理规范使用。 |
| ABSTRACT： | The prevalence of diabetes in China is increasing year by year， and has become a health issue of close concern to the whole society. Glucagon-like peptide-1 （GLP-1） receptor agonist （GLP-1RA）， as a new class of glucose-lowering drugs， is now widely used in the treatment of type 2 diabetes mellitus （T2DM） because of its significant glucose-lowering efficacy and low risk of hypoglycemia. As the level of evidence for its effects on improving cardiovascular system and renal protection and reducing body mass continues to improve， its status in the treatment guidelines for T2DM is gradually increasing. Currently， nine GLP-1RA drugs have been approved for the clinical treatment of T2DM in China. Although all of these drugs exert hypoglycemic effects based on the activation of GLP-1 receptors in the body， the differences in their own structures and natural GLP-1 amino acid homology lead to large differences in pharmacokinetic parameters and clinical efficacy among different analogs. In order to enable clinicians and pharmacists to have a full understanding of the characteristics and clinical evidence of these analogs and to better perform their therapeutic effects， Liaoning Provincial Pharmaceutical Society organized clinical medicine and pharmacy experts to develop a medication guide for nine GLP-1RA drugs to provide a reference for clinical medication needs and promote rational and standardized use by compiling and summarizing the pharmacological characteristics， clinical applications， adverse reactions， interactions， the medications in special populations and medication management. |
| 期刊： | 2023年第34卷第11期 |
| 作者： | 司海娇；肇丽梅；蔡爽；王可可；王家鑫；高飞；刘慧霞；孙鸣；汪宇；刘彤 |
| AUTHORS： | SI Haijiao， ZHAO Limei，CAI Shuang，WANG Keke，WANG Jiaxin，GAO Fei，LIU Huixia，SUN Ming，WANG Yu，LIU Tong |
| 关键字： | 2型糖尿病；胰高血糖素样肽1受体激动剂；合理用药；用药指导 |
| KEYWORDS： | type 2 diabetes mellitus； glucagon-like |
| 阅读数： | 363 次 |
| 本月下载数： | 64 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
